J. Parra

发表

The N and C Termini of the Splice Variants of the Human Mitogen-Activated Protein Kinase-Interacting Kinase Mnk2 Determine Activity and Localization

G. Scheper, C. Proud, Ze-Guang Han, 2003, Molecular and Cellular Biology.

Use of Western blotting filtration to detect UV-cross-linked protein: RNA complexes.

S. Vilaró, M. Reina, M. Buxadé, 2006, Analytical biochemistry.

Features of the Catalytic Domains and C Termini of the MAPK Signal-integrating Kinases Mnk1 and Mnk2 Determine Their Differing Activities and Regulatory Properties*

C. Proud, M. Buxadé, J. Parra, 2005, Journal of Biological Chemistry.

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.

W. Hahn, J. Baselga, S. Kim, 2013, The Journal of clinical investigation.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

J. Baselga, C. García-echeverría, J. Arribas, 2008, Cancer research.

Abstract C114: Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation.

J. Baselga, E. Felip, P. Nuciforo, 2013 .

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

X. Puente, J. Baselga, E. Felip, 2013, Cancer discovery.

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

S. Chandarlapaty, J. Baselga, N. Rosen, 2011, Oncogene.

NVP-BEZ 235 , a Dual PI 3 K / mTOR Inhibitor , Prevents PI 3 K Signaling and Inhibits the Growth of Cancer Cells with Activating PI 3 K Mutations

Violeta Serra, Maurizio Scaltriti, J. Baselga, 2008 .

Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

L. de la Peña, E. Adrover, P. Zamora, 2019, Therapeutic advances in medical oncology.

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

S. Chandarlapaty, J. Baselga, H. Gómez, 2010, Clinical Cancer Research.

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

J. Baselga, J. Arribas, C. Verma, 2009, Oncogene.

The C Terminus of Initiation Factor 4E-Binding Protein 1 Contains Multiple Regulatory Features That Influence Its Function and Phosphorylation

C. Proud, Xuemin Wang, Wei Li, 2003, Molecular and Cellular Biology.

The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1.

Rodolfo Marquez, Jenny Bain, C. Proud, 2005, Immunity.

High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab

M. Piccart, L. Pusztai, J. Baselga, 2014, Clinical Cancer Research.

Abstract P1-08-42: High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial

M. Piccart, L. Pusztai, J. Baselga, 2013 .

Evidence for Direct Protein-Protein Interaction between Members of the Enterobacterial Hha/YmoA and H-NS Families of Proteins

A. Juárez, C. Madrid, E. Miquelay, 2002, Journal of bacteriology.

An antisense oligonucleotide targeting TGF-&bgr;2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages

J. Seoane, M. Janicot, A. Arias, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.